This study investigates primary caregiver perspectives on long-term experiences of caring for individuals with schizophrenia in Thailand. Study participants were 30 caregivers in the Bangkok Metropolitan Area (BMA). Data were collected by semi-structured qualitative interview and analyzed by thematic analysis. Participants defined psychotic symptoms as symptoms requiring prevention and good care, which caregivers must learn to live with. Caregivers were reported to have "acquired experience in controlling psychotic symptoms and recognizing frequency, timing, content, warning signs, and patient response." Schizophrenic patients experienced difficulty engaging in community activities and encountered teasing, stigma, and social isolation. These findings suggest that caregivers saw psychotic symptoms as necessarily leading to ongoing serious problems. The difficulty of dealing with such symptoms was aggravated by caregiver poverty, emotional condition, and advanced age. Innovations in psychiatric and mental health nursing intervention are needed, including psycho-educational community activities to confront the teasing, stigma, and social isolation of individuals with schizophrenia. Simulation applications on mobile phones and Internet are recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01612840.2018.1488312 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics.
Expert Opin Drug Discov
January 2025
Centro de Investigación en Reproducción Animal Universidad Autónoma de Tlaxcala - CINVESTAV Tlaxcala, Tlaxcala, México.
Introduction: Existing pharmacotherapies for schizophrenia have not progressed beyond targeting dopamine and serotonin neurotransmission. Rodent models of schizophrenia are a necessary tool for elucidating neuropathological processes and testing potential pharmacotherapies, but positive preclinical results in rodent models often do not translate to positive results in the clinic.
Areas Covered: The authors reviewed PubMed for studies that applied rodent behavioral models of schizophrenia to assess the antipsychotic potential of several novel pharmacotherapies currently under investigation.
The Neurodiversity Framework in Medicine: On the Spectrum.
Dev Neurobiol
January 2025
Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.
The term "neurodiversity" refers to the natural heterogeneity in human neurological functioning, which includes neurodevelopmental differences and other mental health conditions (e.g., autism spectrum disorder [ASD], attention-deficit hyperactivity disorder [ADHD], dyslexia, bipolar disorder, schizophrenia, and depression).
View Article and Find Full Text PDFA Cross-sectional Study of the Length of Stay of Persons with Mental Illnesses and Revenue to a Government Tertiary Neuropsychiatric Hospital Under Ayushman Bharat.
Indian J Psychol Med
January 2025
Psychiatric Rehabilitation Services, Dept. of Psychiatry, Bengaluru, Karnataka, India.
Background: Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) is a health insurance scheme launched by the Government of India (GOI) in 2018 to cover the in-patient (IP) treatment expenditures, including mental illness treatment expenditures, for 500 million Indians. AB-PMJAY pays 100% of treatment expenditures for persons below the poverty line (BPL) and 30% for people above the poverty line (APL). Ayushman Bharat Arogya Karnataka (ABAK) trust implements this scheme in Karnataka, a southern Indian state.
View Article and Find Full Text PDFSalivary cortisol measures across the clinical stages of psychosis: An individual participant data (IPD) meta-analysis.
Psychoneuroendocrinology
January 2025
King's College London, Institute of Psychiatry, Psychology & Neuroscience, Department of Psychosis Studies, London, UK; National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK; Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address:
Background: Studies of salivary cortisol levels in psychosis have yielded inconsistent findings, which may be attributable to heterogeneity in cortisol measurement, illness stage, and approaches to dealing with sampling factors and potential confounders. To address these issues, we performed an individual participant data (IPD) meta-analysis comparing individuals at different stages of psychosis to controls using five different salivary cortisol measures and explored potential effect modifiers.
Methods: Salivary cortisol data from five London-based cohorts were used to derive the cortisol awakening response, total daytime cortisol output, basal cortisol, and diurnal slope measures (wake-to-evening and peak-to-evening).
Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies.
JMIR Ment Health
January 2025
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
Background: Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!